Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease
Executive Summary
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.
You may also be interested in...
As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
FDA Approval For Novartis’s Sickle Cell Treatment Adakveo
One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.
Sickle Cell Disease Market Snapshot: "The Time Has Come"
Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
